Financials and Corporate

Revenue of 14.3 million euros including payments from Bristol-Myers Squibb and research tax credit Strong cash position with 32.6 million euros in cash, cash equivalents and current financial...

Revenue of 8.0 million euros Cash position as at September 30, 2012 of 32.3 million euros Change to the supervisory board Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces its second participation to...

Three-year cash horizon resulting from collaboration and licensing agreement with Bristol-Myers Squibb Significant advance of the IPH21 program with the regulatory authorization to start the first...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that its Annual General Meeting (“AGM”) took place on June 28, 2012, in Marseilles, France. A number of 21,148,778 votes were expressed out...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 28, 2012, at 9:30 am in its headquarters, 117 avenue de Luminy, F-13009...